[{"id":"aaa379a5-f521-49bd-b248-eb6f907e780f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01349088","created_at":"2021-01-18T05:30:36.786Z","updated_at":"2024-07-02T16:37:28.328Z","phase":"Phase 1/2","brief_title":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","source_id_and_acronym":"NCT01349088","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" HER-2 • PGR • KIT","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2 • PGR • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Ixempra (ixabepilone) • motesanib (AMG 706) • patupilone (EPO 906)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2013","start_date":" 12/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2016-10-21"}]